Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2023 Nice Insight Reports
Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking
Monoclonal Antibody & Recombinant Protein: 2023 Market Analysis, CDMO Pricing and Benchmarking
mRNA Vaccines & Therapeutics: 2023 Market Analysis, CDMO Pricing and Benchmarking
Sterile Drug Product: 2023 Market Analysis, CDMO Pricing and Benchmarking
Active Pharmaceutical Ingredients: 2023 Market Analysis, CDMO Pricing and Benchmarking
Antibody Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking
Contract Research Organizations: 2023 Market Analysis, Pricing and Benchmarking
Oral Solid Dosage: 2023 Market Analysis, CDMO Pricing and Benchmarking
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
BIOVECTRA
23 Articles Available
Can't find what you're looking for? Try our
advanced search
.
International Markets
In what international markets do you anticipate significant developments in the near future?
PAO-01-23-RT-02
Disruptive Technology
What do you view as the most disruptive or transformational technology or development on the horizon?
PAO-01-23-RT-01
mRNA
Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects
PAO-02-022-CL-07
CDMO
Looking to Another 50 Years of Growth
PAO-02-22-R250-01
mRNA Vaccines
BIOVECTRA mRNA Vaccine and Biomanufacturing Facility Announced
PR-M11-21-02
Single-Use Technology
Facilitating Clinical Manufacturing of Recombinant Proteins with Large-Scale Single-Use Fermentation Technology
PAO-10-21-CL-08
Rebranding
BIOVECTRA Inc. Looks Inward for New Brand: It’s All About Care
PR-M06-21-013
Branding
BioVectra's Strategic Brand Update
PTV-06-21-CL-001
Strategic Growth
Planning for Growth as Blockbusters Give Way to Personalized Medicine
PAO-04-22-R221-54
Partnership
BioVectra and PhaseBio Discuss Creating an Optimal Partnership
PTV-04-21-CL-001
Supply Agreement
PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
PR-M11-20-048
Meeting Two Trip Sponsors in Bratislava
Complex Manufacturing
Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation
PAP-Q1-20-CL-017
Recruitment
Living in Canada’s Coastal Paradise
PAP-Q3-19-CL-004
Transaction
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
PR-M09-19-NI-037
Expansion
Announcing Expansion for Enhanced Capabilities
PTV-M08-19-BIO-004
Company Overview
Come Home to BioVectra
PAP-Q2-2019-CL-008
Small Molecule API
Supporting Client Projects for CDMO Success
PAP-Q1-2019-CL-030
Strategic Partnership
BioVectra and Keryx Expand Strategic API Supply Relationship
PAO-M12-17-NI-030
Capacity Expansion
BioVectra on the Road to BIO: Bridging Microbial Demand with Expanded Capacity
PTV-M06-17-CL-004
Microbial Fermentation
BioVectra Inc. to Increase Capacity by Forty Percent
PAO-M05-17-NI-032
Joint Venture Contract Services – A CDMO’s Approach to Being a True Partner
PAP-Q03-16-CL-016
Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies
PAP-Q02-16-CL-007
